Italia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
162,22+7,68 (+4,97%)
Alla chiusura: 04:00PM EST
163,45 +1,23 (+0,76%)
Dopo ore: 07:59PM EST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

    First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of th

  • GlobeNewswire

    BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

    Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on average two months prior to officially receiving the designation Study introduces a new method of combining publicly available SARS-CoV-2 sequence information with predictive analytics to effectively detect and monitor potential high-risk variants which could help increase preparedness against future

  • GlobeNewswire

    BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

    Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTechBioNTech will hold exclusive worldwide development and commercialization rights to all immunotherapies arising from the collaborationCrescendo will receive $40 million upfront, including a cash payment and an equity investment from